Wells Fargo
KYMR icon

Wells Fargo’s Kymera Therapeutics KYMR Stock Holding History

Wells Fargo’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.27M Buy
72,160
+45,393
+170% +$3.9M ﹤0.01% 2361
2026
Q1 		$2.23M Sell
26,767
-39,722
-60% -$3.15M ﹤0.01% 3196
2025
Q4 		$5.17M Buy
66,489
+34,428
+107% +$2.32M ﹤0.01% 2647
2025
Q3 		$1.81M Buy
32,061
+6,490
+25% +$293K ﹤0.01% 3382
2025
Q2 		$1.12M Buy
25,571
+3,138
+14% +$108K ﹤0.01% 3618
2025
Q1 		$614K Buy
22,433
+494
+2% +$18K ﹤0.01% 3946
2024
Q4 		$883K Buy
21,939
+7,487
+52% +$338K ﹤0.01% 3793
2024
Q3 		$684K Buy
14,452
+73
+0.5% +$3.22K ﹤0.01% 3795
2024
Q2 		$429K Buy
14,379
+1,321
+10% +$45.7K ﹤0.01% 4012
2024
Q1 		$525K Buy
13,058
+2,268
+21% +$81.1K ﹤0.01% 3850
2023
Q4 		$275K Sell
10,790
-25,483
-70% -$456K ﹤0.01% 4267
2023
Q3 		$504K Sell
36,273
-16,888
-32% -$340K ﹤0.01% 3779
2023
Q2 		$1.22M Buy
53,161
+10,884
+26% +$312K ﹤0.01% 3320
2023
Q1 		$1.25M Buy
42,277
+40,240
+1,975% +$1.3M ﹤0.01% 3224
2022
Q4 		$50.8K Sell
2,037
-1,470
-42% -$39.2K ﹤0.01% 4848
2022
Q3 		$77K Sell
3,507
-5,656
-62% -$149K ﹤0.01% 4745
2022
Q2 		$180K Sell
9,163
-9,304
-50% -$217K ﹤0.01% 4334
2022
Q1 		$782K Sell
18,467
-10,899
-37% -$460K ﹤0.01% 4083
2021
Q4 		$1.86M Sell
29,366
-6,116
-17% -$356K ﹤0.01% 3572
2021
Q3 		$2.08M Buy
35,482
+34,052
+2,381% +$1.97M ﹤0.01% 3639
2021
Q2 		$69K Buy
1,430
+541
+61% +$23.5K ﹤0.01% 5436
2021
Q1 		$34K Sell
889
-9,898
-92% -$596K ﹤0.01% 5992
2020
Q4 		$669K Buy
+10,787
New +$526K ﹤0.01% 4311

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Wells Fargo's KYMR Position: Q2 2026 in Review

Wells Fargo increased its Kymera Therapeutics (KYMR) stake by 170% in Q2 2026, buying an estimated $3.9M and bringing the position to 72,160 shares worth $8.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

Wells Fargo first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Wells Fargo held 72,160 shares of Kymera Therapeutics worth $8.27M as of Q2 2026.
  • Wells Fargo bought 45,393 Kymera Therapeutics shares in Q2 2026, an estimated $3.9M.
  • Kymera Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2361 holding.
  • Wells Fargo first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.